CVS/pharmacy, the nation's leading retail pharmacy, and MinuteClinic, the largest retail health care clinic provider in the U.S., today announced that flu vaccinations are now available at all of its locations nationwide. CVS/pharmacy has more than 7,000 locations and MinuteClinic has more than 500 locations inside select CVS/pharmacy stores.

Two experimental treatments protected more than 60 percent of monkeys infected with Ebola and all the monkeys infected with a related virus called Marburg, the team at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) in Fort Detrick, Maryland reported.

AVI BioPharma already has a contract worth up to $291 million from the U.S. Department of Defense to develop Ebola treatments.

Entelos, Inc., a simulation and modeling company focused on human health, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,654,955 entitled "Apparatus and Methods for Assessing Metabolic Substrate Utilization" to the Company. These methods further strengthen the Entelos® Metabolism PhysioLab® platform and leverage insights about human physiology that can lead to improved diagnosis, clinical testing, and personalized treatment across a highly variable patient population. This method may also be used to improve the selection of patients for clinical trials of metabolic therapies and diagnostics.

JEOL USA is pleased to announce that the University of Texas El Paso (UTEP) has selected a JEOL cryo-electron microscope for its emerging structural biology program. The instrument, a Transmission Electron Microscope (TEM) will be housed in a new building planned for completion in 2011 on the UTEP campus. The JEM-3200FS that was ordered from JEOL USA is a 300 keV cryo-TEM with an omega energy filter for increased contrast and high resolution.

Australian biopharmaceutical development company BioDiem Ltd (ASX: BDM) announced that it has commenced discussions regarding the manufacturing and marketing rights of its LAIV technology for the Japanese market. Japan is the second largest pharmaceutical market in the world. BioDiem, which previously held the co-marketing rights in conjunction with Nobilon, whose parent company Schering-Plough has recently merged with Merck, has now claimed full rights to that market. The reversion of the rights means that Merck is relieved of the requirement to pay the final milestone payment of US$1m to the Company in accordance with the arrangement in the licence agreement signed in 2004.

OncoGenex Pharmaceuticals, Inc. , today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers.

Palatin Technologies, Inc. announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its U.S. Patent Application Number 11/694,260, titled "Cyclic Natriuretic Peptide Constructs." Allowed claims cover a family of cyclic compounds that bind to natriuretic peptide receptor A (NPRA), including PL-3994, Palatin's lead heart failure drug candidate. Palatin expects the patent will issue in the second half of 2009; the patent's 20-year term would expire in 2027.

China-Biotics, Inc. ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced it has submitted applications for four patents to the State Intellectual Property Office of the People's Republic of China.

Lotus Pharmaceuticals, Inc. ("Lotus" or the "Company") a growing developer and producer of prescriptions drugs and licensed national seller of pharmaceutical products in the People's Republic of China, today reported it received notice of patent pending from the State Intellectual Property Office of the People's Republic of China for its innovative patent application of Gliclazide-Controlled Release Tablets submitted in 2008. Meanwhile, Gliclazide-Controlled Release Tablets has undergone pre-clinical evaluation approved by the State Food and Drug Administration in 2009.